Browse NPR1

Summary
SymbolNPR1
Namenatriuretic peptide receptor 1
Aliases GUCY2A; ANPa; guanylate cyclase A; ANPRA; NPRA; atrionatriuretic peptide receptor A; natriuretic peptide rec ......
Chromosomal Location1q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF01094 Receptor family ligand binding region
PF00211 Adenylate and Guanylate cyclase catalytic domain
PF07714 Protein tyrosine kinase
Function

Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001558 regulation of cell growth
GO:0003013 circulatory system process
GO:0003014 renal system process
GO:0003015 heart process
GO:0003018 vascular process in circulatory system
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006182 cGMP biosynthetic process
GO:0006584 catecholamine metabolic process
GO:0007168 receptor guanylyl cyclase signaling pathway
GO:0007588 excretion
GO:0007589 body fluid secretion
GO:0008015 blood circulation
GO:0008016 regulation of heart contraction
GO:0008217 regulation of blood pressure
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0009712 catechol-containing compound metabolic process
GO:0016049 cell growth
GO:0016525 negative regulation of angiogenesis
GO:0018958 phenol-containing compound metabolic process
GO:0030308 negative regulation of cell growth
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030804 positive regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030810 positive regulation of nucleotide biosynthetic process
GO:0030823 regulation of cGMP metabolic process
GO:0030825 positive regulation of cGMP metabolic process
GO:0030826 regulation of cGMP biosynthetic process
GO:0030828 positive regulation of cGMP biosynthetic process
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0033002 muscle cell proliferation
GO:0035150 regulation of tube size
GO:0035637 multicellular organismal signaling
GO:0035809 regulation of urine volume
GO:0035810 positive regulation of urine volume
GO:0035812 renal sodium excretion
GO:0035813 regulation of renal sodium excretion
GO:0035815 positive regulation of renal sodium excretion
GO:0042311 vasodilation
GO:0042312 regulation of vasodilation
GO:0042417 dopamine metabolic process
GO:0043114 regulation of vascular permeability
GO:0044057 regulation of system process
GO:0044062 regulation of excretion
GO:0045765 regulation of angiogenesis
GO:0045926 negative regulation of growth
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046068 cGMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0048514 blood vessel morphogenesis
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048662 negative regulation of smooth muscle cell proliferation
GO:0050878 regulation of body fluid levels
GO:0050880 regulation of blood vessel size
GO:0051047 positive regulation of secretion
GO:0052652 cyclic purine nucleotide metabolic process
GO:0055067 monovalent inorganic cation homeostasis
GO:0055078 sodium ion homeostasis
GO:0060047 heart contraction
GO:0061337 cardiac conduction
GO:0072522 purine-containing compound biosynthetic process
GO:0090066 regulation of anatomical structure size
GO:0098801 regulation of renal system process
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900373 positive regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1901615 organic hydroxy compound metabolic process
GO:1903522 regulation of blood circulation
GO:1903779 regulation of cardiac conduction
GO:2000021 regulation of ion homeostasis
GO:2000181 negative regulation of blood vessel morphogenesis
Molecular Function GO:0001653 peptide receptor activity
GO:0004383 guanylate cyclase activity
GO:0005525 GTP binding
GO:0008528 G-protein coupled peptide receptor activity
GO:0009975 cyclase activity
GO:0016829 lyase activity
GO:0016849 phosphorus-oxygen lyase activity
GO:0016941 natriuretic peptide receptor activity
GO:0017046 peptide hormone binding
GO:0019001 guanyl nucleotide binding
GO:0032561 guanyl ribonucleotide binding
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0042562 hormone binding
Cellular Component GO:0008074 guanylate cyclase complex, soluble
GO:0043235 receptor complex
GO:0044445 cytosolic part
> KEGG and Reactome Pathway
 
KEGG hsa04022 cGMP-PKG signaling pathway
hsa04024 cAMP signaling pathway
hsa04270 Vascular smooth muscle contraction
hsa04921 Oxytocin signaling pathway
hsa00230 Purine metabolism
Reactome R-HSA-5576891: Cardiac conduction
R-HSA-397014: Muscle contraction
R-HSA-5578768: Physiological factors
Summary
SymbolNPR1
Namenatriuretic peptide receptor 1
Aliases GUCY2A; ANPa; guanylate cyclase A; ANPRA; NPRA; atrionatriuretic peptide receptor A; natriuretic peptide rec ......
Chromosomal Location1q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NPR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNPR1
Namenatriuretic peptide receptor 1
Aliases GUCY2A; ANPa; guanylate cyclase A; ANPRA; NPRA; atrionatriuretic peptide receptor A; natriuretic peptide rec ......
Chromosomal Location1q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NPR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNPR1
Namenatriuretic peptide receptor 1
Aliases GUCY2A; ANPa; guanylate cyclase A; ANPRA; NPRA; atrionatriuretic peptide receptor A; natriuretic peptide rec ......
Chromosomal Location1q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NPR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9490.0205
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0740.241
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8570.235
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1970.676
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0470.98
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5080.817
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1060.831
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3110.731
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6620.53
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7130.641
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4550.472
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3840.00673
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NPR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117011.8-11.80.193
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311018.2-18.20.199
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNPR1
Namenatriuretic peptide receptor 1
Aliases GUCY2A; ANPa; guanylate cyclase A; ANPRA; NPRA; atrionatriuretic peptide receptor A; natriuretic peptide rec ......
Chromosomal Location1q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NPR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNPR1
Namenatriuretic peptide receptor 1
Aliases GUCY2A; ANPa; guanylate cyclase A; ANPRA; NPRA; atrionatriuretic peptide receptor A; natriuretic peptide rec ......
Chromosomal Location1q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NPR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NPR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNPR1
Namenatriuretic peptide receptor 1
Aliases GUCY2A; ANPa; guanylate cyclase A; ANPRA; NPRA; atrionatriuretic peptide receptor A; natriuretic peptide rec ......
Chromosomal Location1q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NPR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNPR1
Namenatriuretic peptide receptor 1
Aliases GUCY2A; ANPa; guanylate cyclase A; ANPRA; NPRA; atrionatriuretic peptide receptor A; natriuretic peptide rec ......
Chromosomal Location1q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NPR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNPR1
Namenatriuretic peptide receptor 1
Aliases GUCY2A; ANPa; guanylate cyclase A; ANPRA; NPRA; atrionatriuretic peptide receptor A; natriuretic peptide rec ......
Chromosomal Location1q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NPR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNPR1
Namenatriuretic peptide receptor 1
Aliases GUCY2A; ANPa; guanylate cyclase A; ANPRA; NPRA; atrionatriuretic peptide receptor A; natriuretic peptide rec ......
Chromosomal Location1q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NPR1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting NPR1.
ID Name Drug Type Targets #Targets
DB00325NitroprussideSmall MoleculeNPR11
DB00727NitroglycerinSmall MoleculeNPR11
DB00883Isosorbide DinitrateSmall MoleculeNPR11
DB01612Amyl NitriteSmall MoleculeNPR11
DB01613Erythrityl TetranitrateSmall MoleculeNPR1, NPR22
DB04899NesiritideBiotechNPR1, NPR2, NPR33
DB05034UlaritideSmall MoleculeNPR11